TCGA-BH-A0HN-01A-11R-A10U-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 17
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CF-A5U8-01A-11R-A28M-07 | — | — | 0.909 |
| 2 | TCGA-LL-A6FP-01A-11R-A31O-07 | — | B | 0.900 |
| 3 | 308a5759-8930-433f-8d11-4c3da6ed0e29 | — | — | 0.900 |
| 4 | TCGA-EW-A423-01A-11R-A24H-07 | — | B | 0.894 |
| 5 | SJEPD001522_R1.RNA-Seq | EPN | EPN Tumor | 0.885 |
| 6 | TCGA-55-6972-01A-11R-1949-07 | — | cohortA2 | 0.884 |
| 7 | TCGA-CF-A47W-01A-11R-A23W-07 | — | — | 0.882 |
| 8 | TCGA-GM-A2DC-01A-11R-A18M-07 | — | B | 0.880 |
| 9 | TCGA-AC-A3YJ-01A-11R-A22U-07 | — | B | 0.875 |
| 10 | BS_V9HVBBDW | Med | Medulloblastoma | 0.875 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 5 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.070 | Remibrutinib | — uncovered |
| PEROXISOME | 0.050 | Idelalisib | — uncovered |